Pacific Biosciences Appoints Kathy Ordonez to Board of Directors
December 18 2014 - 9:00AM
Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of
the PacBio® RS II Sequencing System, today announced that it has
appointed industry veteran Kathy Ordoñez to its Board of Directors.
Ordoñez has a 30 year history of leadership in the life sciences
and diagnostics industries, including positions as Senior Vice
President of Quest Diagnostics, Chief Executive Officer of Celera,
founder of Celera Diagnostics, and President and Chief Executive
Officer for Roche Molecular Systems.
In 2011 Ordoñez joined Quest as part of its acquisition of
Celera and was responsible for the company's Diagnostic Solutions
businesses, including diagnostic products, life insurer services,
clinical trials and healthcare information technology products
until she retired in 2013. Previously, she managed Quest's
innovation pipeline and diagnostic products businesses, led the
Celera business (including Berkeley HeartLab) and was responsible
for driving the company's focus on personalizing disease management
through diagnostic products and services. Prior to the acquisition
by Quest, Ordoñez served as Chief Executive Officer of Celera and
was a founder of Celera Diagnostics. Before joining Celera's parent
company, Applera, in December 2000, Ordoñez held a number of senior
positions over a 15-year period with Hoffmann-La Roche. She oversaw
the formation of Roche Molecular Systems, serving as President and
Chief Executive Officer, and led the application of polymerase
chain reaction technology to the diagnostic, research and forensic
fields.
"With its exquisite sensitivity and accuracy, long-read
sequencing offers tremendous promise for future success in clinical
diagnostics," said Kathy Ordoñez. "The remarkable advances Pacific
Biosciences has demonstrated, which are already transforming
biological studies in the research market, will be critical for
driving the molecular diagnostics field forward. Demand for
sequencing in that market is taking off, and I look forward to
being involved with the company that stands to deliver
unprecedented accuracy and completeness for such a critical
application."
"Kathy is a highly respected life science and diagnostics
executive and we are delighted that she's joining our Board," said
Michael Hunkapiller, Chairman and Chief Executive Officer of
Pacific Biosciences. "Her vision and guidance will be instrumental
in shaping the next phase for PacBio as our products become more
widely established both in the research market and, in the longer
term, through our partnership with Roche Diagnostics."
About the PacBio RS II and SMRT Sequencing
Pacific Biosciences' SMRT Sequencing technology achieves the
industry's longest read lengths, highest consensus accuracy, and
the least degree of bias. These characteristics, combined with the
ability to detect many types of DNA base modifications (e.g.,
methylation) as part of the sequencing process, make the PacBio RS
II an essential tool for many scientists studying genetic and
genomic variation. The PacBio platform provides a sequencing
solution that can address a growing number of complex medical,
agricultural, and industrial problems.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the
PacBio RS II DNA Sequencing System to help scientists solve
genetically complex problems. Based on its novel Single Molecule,
Real-Time (SMRT) technology, the company's products enable:
targeted sequencing to more comprehensively characterize genetic
variations; de novo genome assembly to more fully identify,
annotate, and decipher genomic structures; and DNA base
modification identification to help characterize epigenetic
regulation and DNA damage. By providing access to information that
was previously inaccessible, Pacific Biosciences enables scientists
to increase their understanding of biological systems. More
information is available at www.pacb.com
CONTACT: For Pacific Biosciences:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024